{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaedgyjewq6vk54j5cufmelzcx63vmmoewz7zkxotvru6wpsppp3e",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mez2lgkhbem2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreig5el7zyqrvfcccpotwfji3htuuqhqcbjfrunqcv2z4gb6taqcgxe"
    },
    "mimeType": "image/jpeg",
    "size": 355813
  },
  "path": "/news/2026-02-optimizing-car-cell-therapy-tackle.html",
  "publishedAt": "2026-02-16T16:21:56.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the vicinity of a tumor, such that they do not attack cancer cells. This is one of the reasons why therapeutic CAR T cells have lacked success against solid tumors such as bowel or pancreatic cancer.",
  "title": "Optimizing CAR T-cell therapy to tackle solid tumors"
}